FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1446227957> ?p ?o ?g. }

• W1446227957 endingPage "330" @default.
• W1446227957 startingPage "323" @default.
• W1446227957 abstract "Background The role of chemotherapy in nodal metastases from penile squamous cell carcinoma is not defined. We evaluated the efficacy of a combination of T-PF (a taxane, cisplatin, and 5-fluorouracil) in neoadjuvant and adjuvant settings. Patients and Methods Since June of 2004, T-PF was administered to stage N2 to 3 patients. With time, neoadjuvant chemotherapy administration prevailed with respect to use in the adjuvant setting. Primary end points were progression-free (PFS) and overall (OS) survival. Secondary objectives were tolerability and activity in the neoadjuvant setting. Nonparametric tests, Kaplan–Meier, and regression analyses were performed. Results As of October of 2012, 47 consecutive N2 to 3 M0 patients had undergone neoadjuvant (n = 28) or adjuvant (n = 19) T-PF: 18 patients (38.3%) remain disease-free after a median follow-up of 22 months (interquartile range, 17-42 months). The 2-year disease-free survivals were 36.8% (95% confidence interval [CI], 15.2-58.5) versus 7.1% (95% CI, 0-16.7) after adjuvant and neoadjuvant therapy, respectively. N3 metastases were associated with a poorer PFS, and bilateral metastases and mutated p53 were associated with a poorer OS. After neoadjuvant treatment, 43% clinical responses and 14% complete pathologic remissions were recorded, but responses were not associated with survival. Neutropenia (25.5%) was the most frequent Grade ≥ 2 toxicity. Conclusion The T-PF regimen is well tolerated and compares with other regimens in terms of activity and efficacy in the neoadjuvant setting, and very long survivals have been recorded after adjuvant administration. The role of perioperative treatment in these patients remains controversial. Some caution in administering preemptive treatment in patients with resectable disease is needed." @default.
• W1446227957 created "2016-06-24" @default.
• W1446227957 creator A5004236203 @default.
• W1446227957 creator A5012466586 @default.
• W1446227957 creator A5024954730 @default.
• W1446227957 creator A5028798959 @default.
• W1446227957 creator A5057175197 @default.
• W1446227957 creator A5058115974 @default.
• W1446227957 creator A5058849092 @default.
• W1446227957 creator A5064013596 @default.
• W1446227957 creator A5065061650 @default.
• W1446227957 creator A5067994961 @default.
• W1446227957 creator A5080811290 @default.
• W1446227957 creator A5083331837 @default.
• W1446227957 creator A5085121255 @default.
• W1446227957 creator A5086507632 @default.
• W1446227957 creator A5090061046 @default.
• W1446227957 date "2016-08-01" @default.
• W1446227957 modified "2023-10-17" @default.
• W1446227957 title "A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings" @default.
• W1446227957 cites W1964187644 @default.
• W1446227957 cites W1971281344 @default.
• W1446227957 cites W1973333007 @default.
• W1446227957 cites W1983970003 @default.
• W1446227957 cites W1991013965 @default.
• W1446227957 cites W2019028826 @default.
• W1446227957 cites W2034498859 @default.
• W1446227957 cites W2052912631 @default.
• W1446227957 cites W2055103764 @default.
• W1446227957 cites W2076300269 @default.
• W1446227957 cites W2091048118 @default.
• W1446227957 cites W2101270203 @default.
• W1446227957 cites W2112412554 @default.
• W1446227957 cites W2137178561 @default.
• W1446227957 cites W2141592118 @default.
• W1446227957 cites W2158426906 @default.
• W1446227957 cites W2170568040 @default.
• W1446227957 cites W4293241248 @default.
• W1446227957 cites W81093646 @default.
• W1446227957 doi "https://doi.org/10.1016/j.clgc.2015.07.009" @default.
• W1446227957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26341040" @default.
• W1446227957 hasPublicationYear "2016" @default.
• W1446227957 type Work @default.
• W1446227957 sameAs 1446227957 @default.
• W1446227957 citedByCount "57" @default.
• W1446227957 countsByYear W14462279572016 @default.
• W1446227957 countsByYear W14462279572017 @default.
• W1446227957 countsByYear W14462279572018 @default.
• W1446227957 countsByYear W14462279572019 @default.
• W1446227957 countsByYear W14462279572020 @default.
• W1446227957 countsByYear W14462279572021 @default.
• W1446227957 countsByYear W14462279572022 @default.
• W1446227957 countsByYear W14462279572023 @default.
• W1446227957 crossrefType "journal-article" @default.
• W1446227957 hasAuthorship W1446227957A5004236203 @default.
• W1446227957 hasAuthorship W1446227957A5012466586 @default.
• W1446227957 hasAuthorship W1446227957A5024954730 @default.
• W1446227957 hasAuthorship W1446227957A5028798959 @default.
• W1446227957 hasAuthorship W1446227957A5057175197 @default.
• W1446227957 hasAuthorship W1446227957A5058115974 @default.
• W1446227957 hasAuthorship W1446227957A5058849092 @default.
• W1446227957 hasAuthorship W1446227957A5064013596 @default.
• W1446227957 hasAuthorship W1446227957A5065061650 @default.
• W1446227957 hasAuthorship W1446227957A5067994961 @default.
• W1446227957 hasAuthorship W1446227957A5080811290 @default.
• W1446227957 hasAuthorship W1446227957A5083331837 @default.
• W1446227957 hasAuthorship W1446227957A5085121255 @default.
• W1446227957 hasAuthorship W1446227957A5086507632 @default.
• W1446227957 hasAuthorship W1446227957A5090061046 @default.
• W1446227957 hasConcept C119060515 @default.
• W1446227957 hasConcept C121608353 @default.
• W1446227957 hasConcept C126322002 @default.
• W1446227957 hasConcept C141071460 @default.
• W1446227957 hasConcept C143998085 @default.
• W1446227957 hasConcept C2776694085 @default.
• W1446227957 hasConcept C2777063308 @default.
• W1446227957 hasConcept C2777180808 @default.
• W1446227957 hasConcept C2777511904 @default.
• W1446227957 hasConcept C2778292576 @default.
• W1446227957 hasConcept C2780456651 @default.
• W1446227957 hasConcept C2781413609 @default.
• W1446227957 hasConcept C530470458 @default.
• W1446227957 hasConcept C71924100 @default.
• W1446227957 hasConceptScore W1446227957C119060515 @default.
• W1446227957 hasConceptScore W1446227957C121608353 @default.
• W1446227957 hasConceptScore W1446227957C126322002 @default.
• W1446227957 hasConceptScore W1446227957C141071460 @default.
• W1446227957 hasConceptScore W1446227957C143998085 @default.
• W1446227957 hasConceptScore W1446227957C2776694085 @default.
• W1446227957 hasConceptScore W1446227957C2777063308 @default.
• W1446227957 hasConceptScore W1446227957C2777180808 @default.
• W1446227957 hasConceptScore W1446227957C2777511904 @default.
• W1446227957 hasConceptScore W1446227957C2778292576 @default.
• W1446227957 hasConceptScore W1446227957C2780456651 @default.
• W1446227957 hasConceptScore W1446227957C2781413609 @default.
• W1446227957 hasConceptScore W1446227957C530470458 @default.
• W1446227957 hasConceptScore W1446227957C71924100 @default.
• W1446227957 hasIssue "4" @default.

• next